[225Ac]Ac-DOTATATE Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1: 2

Top Sponsors

Peking University Cancer Hospital & Institute2

Indications

Cancer2
Neuroendocrine Neoplasm1
SCLC,Extensive Stage1
Lung Cancer1

Other2 trials

A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens

Phase 1

A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.